3-O-Acetyl-11-keto- β -boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma
© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V..
Glioblastoma is the most common and aggressive primary tumor in the central nervous system, accounting for 12%-15% of all brain tumors. 3-O-Acetyl-11-keto-β-boswellic acid (AKBA), one of the most active ingredients of gum resin from Boswellia carteri Birdw., was reported to inhibit the growth of glioblastoma cells and subcutaneous glioblastoma. However, whether AKBA has antitumor effects on orthotopic glioblastoma and the underlying mechanisms are still unclear. An orthotopic mouse model was used to evaluate the anti-glioblastoma effects of AKBA. The effects of AKBA on tumor growth were evaluated using MRI. The effects on the alteration of metabolic landscape were detected by MALDI-MSI. The underlying mechanisms of autophagy reducing by AKBA treatment were determined by immunoblotting and immunofluorescence, respectively. Transmission electron microscope was used to check morphology of cells treated by AKBA. Our results showed that AKBA (100 mg/kg) significantly inhibited the growth of orthotopic U87-MG gliomas. Results from MALDI-MSI showed that AKBA improved the metabolic profile of mice with glioblastoma, while immunoblot assays revealed that AKBA suppressed the expression of ATG5, p62, LC3B, p-ERK/ERK, and P53, and increased the ratio of p-mTOR/mTOR. Taken together, these results suggested that the antitumor effects of AKBA were related to the normalization of aberrant metabolism in the glioblastoma and the inhibition of autophagy. AKBA could be a promising chemotherapy drug for glioblastoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Acta pharmaceutica Sinica. B - 10(2020), 2 vom: 14. Feb., Seite 301-312 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Wan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.apsb.2019.12.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306765705 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306765705 | ||
| 003 | DE-627 | ||
| 005 | 20231225124106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.apsb.2019.12.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1022.xml |
| 035 | |a (DE-627)NLM306765705 | ||
| 035 | |a (NLM)32082975 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Wan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 3-O-Acetyl-11-keto- β -boswellic acid ameliorated aberrant metabolic landscape and inhibited autophagy in glioblastoma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. | ||
| 520 | |a Glioblastoma is the most common and aggressive primary tumor in the central nervous system, accounting for 12%-15% of all brain tumors. 3-O-Acetyl-11-keto-β-boswellic acid (AKBA), one of the most active ingredients of gum resin from Boswellia carteri Birdw., was reported to inhibit the growth of glioblastoma cells and subcutaneous glioblastoma. However, whether AKBA has antitumor effects on orthotopic glioblastoma and the underlying mechanisms are still unclear. An orthotopic mouse model was used to evaluate the anti-glioblastoma effects of AKBA. The effects of AKBA on tumor growth were evaluated using MRI. The effects on the alteration of metabolic landscape were detected by MALDI-MSI. The underlying mechanisms of autophagy reducing by AKBA treatment were determined by immunoblotting and immunofluorescence, respectively. Transmission electron microscope was used to check morphology of cells treated by AKBA. Our results showed that AKBA (100 mg/kg) significantly inhibited the growth of orthotopic U87-MG gliomas. Results from MALDI-MSI showed that AKBA improved the metabolic profile of mice with glioblastoma, while immunoblot assays revealed that AKBA suppressed the expression of ATG5, p62, LC3B, p-ERK/ERK, and P53, and increased the ratio of p-mTOR/mTOR. Taken together, these results suggested that the antitumor effects of AKBA were related to the normalization of aberrant metabolism in the glioblastoma and the inhibition of autophagy. AKBA could be a promising chemotherapy drug for glioblastoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AKBA | |
| 650 | 4 | |a AKBA, 3-O-acetyl-11-keto-β-boswellic acid | |
| 650 | 4 | |a Autophagy | |
| 650 | 4 | |a DAPI, 4′,-6-diamidino-2-phenylindole | |
| 650 | 4 | |a G3P, glycerol-3-phosphate | |
| 650 | 4 | |a G6P, glucose-6-phosphate | |
| 650 | 4 | |a GBM, glioblastomas | |
| 650 | 4 | |a GL/FFA, glycerolipid/free fatty acid | |
| 650 | 4 | |a Glioblastoma | |
| 650 | 4 | |a IDH1/2, isocitrate dehydrogenases 1/2 | |
| 650 | 4 | |a ITO, indium tin oxide | |
| 650 | 4 | |a LA, linoleic acid | |
| 650 | 4 | |a MALDI-MSI | |
| 650 | 4 | |a MALDI-MSI, matrix-assisted laser desorption ionization-mass spectrometry imaging | |
| 650 | 4 | |a NAA, N-acetyl-l-aspartic acid | |
| 650 | 4 | |a NEDC, N-(1-naphthyl) ethylenediamine dihydrochloride | |
| 650 | 4 | |a OA, oleic acid | |
| 650 | 4 | |a PA, phosphatidic acid | |
| 650 | 4 | |a PE, phosphatidylethanolamine | |
| 650 | 4 | |a PG, phosphatidylglycerols | |
| 650 | 4 | |a PI, phosphatidylinositol | |
| 650 | 4 | |a PS, phosphatidylserine | |
| 650 | 4 | |a Phospholipids | |
| 650 | 4 | |a TIC, total ion current | |
| 650 | 4 | |a TMZ, temozolomide | |
| 700 | 1 | |a Ren, Liwen |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xiangjin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jinyi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jinhua |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Tengfei |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Guanhua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmaceutica Sinica. B |d 2012 |g 10(2020), 2 vom: 14. Feb., Seite 301-312 |w (DE-627)NLM227628217 |x 2211-3835 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:2 |g day:14 |g month:02 |g pages:301-312 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.apsb.2019.12.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 2 |b 14 |c 02 |h 301-312 | ||